The deal represents a “rational bit of self-help” for Bluebird, SVB Leerink analyst Mani Foroohar wrote in a note to investors. While it’s unusual for such a specialized company to give up part of its in-house production, Bluebird has run into a series of manufacturing-related delays. Added cash and cost savings could help reassure shareholders.
National Resilience, meanwhile, is quickly building a significant North American network to fulfill its goal of developing “the world’s most advanced biopharmaceutical manufacturing ecosystem.” Founded last November, the company started out with more than $800 million in capital and a focus on cutting-edge medicines such as cell and gene therapies.
